TACSTD2 and hematologic disorder: The target antigens of the FDA licensed ADCs are CD19, CD22, CD30, CD33, and CD79b in hematological malignancies and HER2, trop2, nectin4, tissue factor, and folate receptor alpha (FRα) in solid cancers as illustrated in Table 1.